Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Adrianna Henson-Masters"'
Autor:
Claire Christine Baniel, Sara Beltrán Ponce, Katie E. Lichter, Gabrielle W. Peters, Christina Small, Crystal Seldon, Katarina T. Nguyen, Amanda Farah Khan, Charles R. Thomas, William Small, Jenna M. Kahn, Kenneth R. Olivier, Adrianna Henson Masters, Parul N. Barry, Erqi L. Pollom, Reshma Jagsi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 116:270-275
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcc73d1e11434f29de59d29c35e0086a
https://doi.org/10.1016/j.ijrobp.2022.12.027
https://doi.org/10.1016/j.ijrobp.2022.12.027
Autor:
Jaroslaw T. Hepel, Boris Pasche, Ralph B. D'Agostino, Joseph N. Contessa, Stephen B. Tatter, Albert Attia, Brandi R. Page, Christopher D. Corso, Manmeet Ahluwalia, Lawrence Kleinberg, Samuel T. Chao, Caroline Chung, Michael Farris, D.N. Ayala-Peacock, Emory R. McTyre, Colette J. Shen, Christina K. Cramer, Jing Su, Kounosuke Watabe, Jimmy Ruiz, Adrian W. Laxton, Adrianna Henson-Masters, Michael H. Soike, Rupesh Kotecha, Veronica Chiang, John B. Fiveash, Michael D. Chan, Steve Braunstein
Publikováno v:
Radiotherapy and Oncology. 142:168-174
Brain metastasis velocity (BMV) is a prognostic metric that describes the recurrence rate of new brain metastases after initial treatment with radiosurgery (SRS). We have previously risk stratified patients into high, intermediate, and low-risk BMV g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f59550ac1bd33e6222d86471e76a007
https://doi.org/10.1016/j.radonc.2019.08.011
https://doi.org/10.1016/j.radonc.2019.08.011
Autor:
Daniel Doheny, Hui-Wen Lo, Angelina T. Regua, Marlyn Anguelov, Roy E. Strowd, Tadas Rimkus, Sara G. Manore, Sherona Sirkisoon, Adrianna Henson-Masters, Noah R. Aguayo, Alexandra Thomas, Dongqin Zhu
Publikováno v:
Neuro-oncology Advances
Breast cancer is the second leading cause of brain metastases in women; patients with breast cancer brain metastasis (BCBM) survive an average of 6–18 months following diagnosis. Cancer stem cells are thought to be one of the driving forces behind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a60ce0ac89a045136eb40d9ec66877
https://doi.org/10.1093/noajnl/vdaa073.042
https://doi.org/10.1093/noajnl/vdaa073.042